Prezista (Darunavir) Label Change -- Drug Interaction Information
March 1, 2013
The FDA recently approved changes to the Prezista (darunavir) label to reflect drug interaction information with artemether/lumefantrine. The specific changes are outlined below.
Section 7: Drug Interactions
Antimalarials: artemether/lumefantrine -- No change in darunavir exposures. Decrease in artemether and dihydroartemisinin exposures. Increase in lumefantrine exposures. The combination of Prezista and artemether/lumefantrine can be used without dose adjustments. However, the combination should be used with caution as increased lumefantrine exposure may increase the risk of QT prolongation.
Section 12 Clinical Pharmacology was also updated to include these drug interactions.
You can view the complete, revised label at Drugs@FDA.
Prezista is a product of Janssen Pharmaceuticals.
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)